Role of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies?
Interleukin 6 (IL‐6) can bind to both the soluble (s) and membrane bound (m) forms of the IL‐6 receptor (IL‐6R). On binding of IL‐6, both forms of IL‐6R can activate gp130 and subsequent downstream signalling pathways. The classic activation pathway (A) involves dimerisation of membrane bound IL‐6R with gp130. (B) In tissues where membrane bound IL‐6R is not expressed, soluble IL‐6R (sIL‐6R) can trigger gp130. This trans‐signalling is therefore responsive to localised concentrations of sIL‐6R. When triggered, gp130 activates Janus kinase (JAK) receptor associated kinases, which phosphorylate gp130 and thereby regulate the activity of STAT1/3 and the SHP2 cascade. Among other effects, this triggers negative regulators of these signalling pathways, including suppressor of cytokine signalling (SOCS)‐1 and SOCS3. (C) Soluble gp130 (sgp130) can bind to sIL‐6R and prevent its interaction with membrane bound gp130. This effectively prevents activation of gp130 and subsequent downstream signalling events.
Publication
Role of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies?. (2006) T T Pizarro, et al. Gut. 2006 Sep;55(9):1226-1227. Figure: F1.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | gp130 | GP130 | ncbigene_synonym | IL6ST | 3572 |
| Homo sapiens | Primates | gp130 | GP130 | ncbigene_synonym | NM | 4827 |
| Homo sapiens | Primates | gp130 | GP130 | ncbigene_synonym | LRPPRC | 10128 |
| Homo sapiens | Primates | IL-6 | IL-6 | ncbigene_synonym | IL6 | 3569 |
| Homo sapiens | Primates | IL-6R | IL-6R | ncbigene_synonym | IL6R | 3570 |
| Homo sapiens | Primates | SOCS3 | SOCS3 | ncbigene_symbol | SOCS3 | 9021 |
| Homo sapiens | Primates | SHP2 | SHP2 | ncbigene_synonym | PTPN11 | 5781 |
| Homo sapiens | Primates | STAT3 | STAT3 | ncbigene_symbol | STAT3 | 6774 |
| Homo sapiens | Primates | PI3-K | PI3K | ncbigene_synonym | PIK3CA | 5290 |
| Homo sapiens | Primates | PI3-K | PI3K | ncbigene_synonym | PIK3CB | 5291 |
| Homo sapiens | Primates | PI3-K | PI3K | ncbigene_synonym | PIK3CD | 5293 |
| Homo sapiens | Primates | PI3-K | PI3K | ncbigene_synonym | PIK3CG | 5294 |
| Homo sapiens | Primates | PI3-K | PI3K | famplex_relations | PIK3R3 | 8503 |
| Homo sapiens | Primates | PI3-K | PI3K | famplex_relations | PIK3R4 | 30849 |
| Homo sapiens | Primates | PI3-K | PI3K | famplex_relations | PIK3R5 | 23533 |
| Homo sapiens | Primates | PI3-K | PI3K | famplex_relations | PIK3R6 | 146850 |
| Homo sapiens | Primates | PI3-K | PI3K | famplex_relations | PIK3R1 | 5295 |
| Homo sapiens | Primates | PI3-K | PI3K | famplex_relations | PIK3R2 | 5296 |
| Homo sapiens | Primates | Grb2 | GRB2 | ncbigene_symbol | GRB2 | 2885 |
| Homo sapiens | Primates | Ras | RAS | famplex_relations | KRAS | 3845 |
| Homo sapiens | Primates | Ras | RAS | famplex_relations | HRAS | 3265 |
| Homo sapiens | Primates | Ras | RAS | famplex_relations | NRAS | 4893 |
| Homo sapiens | Primates | Akt | AKT | ncbigene_synonym | AKT1 | 207 |
| Homo sapiens | Primates | Akt | AKT | famplex_relations | AKT2 | 208 |
| Homo sapiens | Primates | Akt | AKT | famplex_relations | AKT3 | 10000 |
| Homo sapiens | Primates | ERK | ERK | ncbigene_synonym | EPHB2 | 2048 |
| Homo sapiens | Primates | ERK | ERK | ncbigene_synonym | MAPK1 | 5594 |
| Homo sapiens | Primates | ERK | ERK | famplex_relations | MAPK3 | 5595 |
| Homo sapiens | Primates | SOCS1 | SOCS1 | ncbigene_symbol | SOCS1 | 8651 |
| Homo sapiens | Primates | JAK | JAK | famplex_relations | JAK1 | 3716 |
| Homo sapiens | Primates | JAK | JAK | famplex_relations | JAK2 | 3717 |
| Homo sapiens | Primates | JAK | JAK | famplex_relations | JAK3 | 3718 |
| Homo sapiens | Primates | JAK | JAK | famplex_relations | TYK2 | 7297 |
| Word | Match | MeSH | Name | ChEBI |
|---|
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|---|---|---|---|
| Cancer | NA |